Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.
Psoriasis
biologics
psoriasis treatment
psoriatic arthritis
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
22
01
2023
accepted:
21
07
2023
pubmed:
1
11
2023
medline:
1
11
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients. Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients.
PATIENTS AND METHODS
METHODS
Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches.
RESULTS
RESULTS
Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started.
CONCLUSIONS
CONCLUSIONS
The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1513-1523Informations de copyright
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961-967.e5.
Purzycka-Bohdan D, Kisielnicka A, Zabłotna M, et al. Chronic plaque psoriasis in poland: disease severity, prevalence of comorbidities, and quality of life. J Clin Med. 2022;11(5):1-16.
Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatology. 2013;149(10):1173-1179.
Augustin M, Girbig G, Kis A, et al. Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs. J Dtsch Dermatol Ges. 2021;19(S5):25-53.
Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatology Venereol. 2019;33(12):2305-2312.
Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936-945.
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatology Venereol. 2018;32(9):1507-1514.
Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674-681.
Xu S, Gao X, Deng J, et al. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges. 2021;19(1):47-56.
Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis*. Br J Dermatol. 2021;184(6):1094-1105.
Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509-519.
Inzinger M, Legat FJ, Hofer A, et al. Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents. Br J Dermatol. 2014;171(4):915-917.
Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: Report from the psoriasis registry Austria. Acta Derm Venereol. 2016;96(2):207-212.
Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: Retrospective data analysis of a patient registry. Br J Dermatol. 2011;165(3):640-645.
Inzinger M, Weger W, Heschl B, et al. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: Data registry report on the efficacy under daily life conditions. J Eur Acad Dermatology Venereol. 2013;27(7):861-866.
Busard CI, Cohen AD, Wolf P, et al. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. J Eur Acad Dermatology Venereol. 2018;32(2):245-253.
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatology Venereol. 2020;34(11):2461-2498.
Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-150.
Ruiz-Genao DP, Carretero G, Rivera R, et al. Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the spanish biobadaderm registry. Actas Dermosifiliogr. 2020;111(9):752-760.
Langenbruch A, Mohr N, Kirsten N, et al. Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017. J Eur Acad Dermatology Venereol. 2021;35(7):1536-1542.
Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: Results of a German national survey. J Eur Acad Dermatology Venereol. 2009;23(6):683-691.
Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-1047.
Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3.” Arch Dermatol Res. 2016;308(6):401-408.
Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078.
Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatology Venereol. 2022;36(11):2087-2100.
Heidbrede T, Mevius A, Kessel S, et al. Real-world systemic treatment of patients with psoriasis: A retrospective study based on German claims data. J Dtsch Dermatol Ges. 2023;21(6):611-619.
Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatology Venereol. 2012;26(SUPPL. 2):12-20.
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393-403.
Kommoss KS, Enk A, Heikenwälder M, et al. Cardiovascular comorbidity in psoriasis - psoriatic inflammation is more than just skin deep. J Dtsch Dermatol Ges. 2023;21(7):718-725.
Kromer C, Mohr J, Celis D, et al. Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment. J Dtsch Dermatol Ges. 2021;19(10):1451-1461.
Pilz AC, Zink A, Schielein MC, et al. Despite large choice of effective therapies: Individuals with psoriasis still seem undertreated. J Dtsch Dermatol Ges. 2021;19(7):1003-1011.
Schön MP, Wilsmann-Theis D. Current developments and perspectives in psoriasis. J Dtsch Dermatol Ges. 2023;21(4):363-372.
Maul JT, Augustin M, Sorbe C, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. Br J Dermatol. 2021;185(6):1160-1168.
Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069-1076.